Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who had SBM\* (Spontaneous bowel movement) less than 3 times per week, more than six months prior to the provisional registration~  * \*Defecation without procedure of laxative, suppository, enema, or stool extraction on the day or preceding day of the defecation~* Patient who was affected with one or more following symptoms before more than six months of provisional registration:~  * Straining during at least 25% of defecations~ * Lumpy or hard stools in at least 25% of defecations~ * Sensation of incomplete evacuation for at least 25% of defecations~* Loose stools are rarely present without the use of laxatives more than six months prior to the provisional registration.~* Patients who had pancolonoscopy or contrast enema (or sigmoidoscopy) after the onset of chronic constipation symptom and had no organic changes~Exclusion Criteria:~* Patient who has met IBS-C diagnostic criteria from Rome III more than six months prior to provisional registration. Meaning that patient who had recurrent abdominal pain or discomfort at least 3 days/month in last 3 months associated with two or more of the following, and patient who was affected with following IBS symptoms more than six months prior to the provisional registration:~  * Improvement with defecation~ * Onset associated with a change in frequency of stool~ * Onset associated with a change in form (appearance) of stool~* Patient with history of surgical resection of stomach, gallbladder, small intestine, or large intestine (excluding resection of appendicitis and benign polyp)~* Patient with history or current evidence of inflammatory bowel disease (Crohn's disease or ulcerative colitis)~* Patient with history or current evidence of ischemic colitis~* Patient currently affected by infectious enteritis~* Patient currently affected by hyperthyroidism or hypothyroidism~* Patient with apparent mechanical obstruction (i.e. patient with ileus caused by hernia)~* Patient with mega colon or mega rectum~* Patient currently affected by constipation due to anorectal dysfunction~* Patient currently affected by drug induced constipation.~* Patient with constipation due to other organic disease~* Patient currently affected by active peptic ulcer~* In the case of a female, the one currently affected by endometriosis or uterine adenomyosis~* Patient with high depression or anxiety considered to influence drug evaluation~* Patient with history of abuse of drug or alcohol within a year before consent acquisition, or with current abuse~* Patient who used or underwent or will use or undergo drug/therapy/test prohibited to combine 3 days before the start of bowel habit observation period (Day -17) or thereafter (however, patient who used or underwent restricted drug/therapy according to Protocol may be enrolled provisionally)~* Patient with history or current evidence of malignant tumor~* Patient currently affected by serious cardiovascular disease, respiratory disease, kidney disease, hepatic disease, gastrointestinal disease (excluding CC), hemorrhagic disease, or neural/mental disease~* Patient with history of drug allergy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- ASP0456 0.0625mg (Type: EXPERIMENTAL): oral
- ASP0456 0.125mg (Type: EXPERIMENTAL): oral
- ASP0456 0.25mg (Type: EXPERIMENTAL): oral
- ASP0456 0.5mg (Type: EXPERIMENTAL): oral
- Placebo group (Type: PLACEBO_COMPARATOR): oral

Based on this trial design, predict the completion outcome and termination type (if applicable).